Refine
Document Type
- Article (2)
- Working Paper (1)
Language
- English (3)
Has Fulltext
- yes (3)
Is part of the Bibliography
- no (3)
Keywords
- Antibodies (1)
- Cats (1)
- Consistency of interest (1)
- Enzyme-linked immunoassays (1)
- Grit (1)
- Invariance testing (1)
- Macrophages (1)
- Monoclonal antibodies (1)
- Perseverance of effort (1)
- Psychometric properties (1)
Non-standard errors
(2021)
In statistics, samples are drawn from a population in a data-generating process (DGP). Standard errors measure the uncertainty in sample estimates of population parameters. In science, evidence is generated to test hypotheses in an evidence-generating process (EGP). We claim that EGP variation across researchers adds uncertainty: non-standard errors. To study them, we let 164 teams test six hypotheses on the same sample. We find that non-standard errors are sizeable, on par with standard errors. Their size (i) co-varies only weakly with team merits, reproducibility, or peer rating, (ii) declines significantly after peer-feedback, and (iii) is underestimated by participants.
Despite its popularity in practice, the Grit-O Scale has shown inconsistent factorial structures and differing levels of internal consistency in samples outside the USA. The validity of the Grit-O Scale in different contexts is, therefore, questionable. As such, the purpose of this paper was to determine whether the Grit-O Scale could be used as a valid and reliable measure to compare grit across different nations. Specifically, the aim was to investigate the factorial validity, reliability, and concurrent validity of the Grit-O Scale and to investigate measurement invariance across three national cohorts (Europe, the USA, and Hong Kong). Data were gathered from 1888 respondents stemming from one USA- (n = 471), two Hong Kong- (n = 361) and four European (n = 1056) universities. A series of traditional CFA and less restrictive ESEM models were estimated and systematically compared to determine the best factorial form of the Grit-O Scale. The results showed that a bifactor ESEM model, with one general factor of overall grit and two specific factors (consistency of interest and perseverance of effort), fitted the data best, showed strong measurement invariance across the three samples, and showed itself to be a reliable measure. Furthermore, concurrent validity was established by showing that the three grit factors were directly and positively related to task performance. Meaningful latent comparisons between the three cultural cohorts could therefore be made. The results imply that cross-national comparisons of grit may only be problematic when traditional CFA approaches are favoured. In contrast, ESEM modelling approaches may compensate for cross-national differences in understanding grit and control for differences in the interpretation of the scale’s items. Therefore, the bifactor ESEM approach may be more appropriate for cross-cultural and cross-national comparison studies, as it allows for these differences to be meaningfully captured, modelled, and controlled for.
Background: Experimental animal data show that protection against severe acute respiratory syndrome coronavirus (SARS-CoV) infection with human monoclonal antibodies (mAbs) is feasible. For an effective immune prophylaxis in humans, broad coverage of different strains of SARS-CoV and control of potential neutralization escape variants will be required. Combinations of virus-neutralizing, noncompeting mAbs may have these properties. Methods and Findings: Human mAb CR3014 has been shown to completely prevent lung pathology and abolish pharyngeal shedding of SARS-CoV in infected ferrets. We generated in vitro SARS-CoV variants escaping neutralization by CR3014, which all had a single P462L mutation in the glycoprotein spike (S) of the escape virus. In vitro experiments confirmed that binding of CR3014 to a recombinant S fragment (amino acid residues 318–510) harboring this mutation was abolished. We therefore screened an antibody-phage library derived from blood of a convalescent SARS patient for antibodies complementary to CR3014. A novel mAb, CR3022, was identified that neutralized CR3014 escape viruses, did not compete with CR3014 for binding to recombinant S1 fragments, and bound to S1 fragments derived from the civet cat SARS-CoV-like strain SZ3. No escape variants could be generated with CR3022. The mixture of both mAbs showed neutralization of SARS-CoV in a synergistic fashion by recognizing different epitopes on the receptor-binding domain. Dose reduction indices of 4.5 and 20.5 were observed for CR3014 and CR3022, respectively, at 100% neutralization. Because enhancement of SARS-CoV infection by subneutralizing antibody concentrations is of concern, we show here that anti-SARS-CoV antibodies do not convert the abortive infection of primary human macrophages by SARS-CoV into a productive one. Conclusions: The combination of two noncompeting human mAbs CR3014 and CR3022 potentially controls immune escape and extends the breadth of protection. At the same time, synergy between CR3014 and CR3022 may allow for a lower total antibody dose to be administered for passive immune prophylaxis of SARS-CoV infection.